Tribal immunity not applicable in IPR, says Fed Circuit

Allergan and the Saint Regis Mohawk Tribe suffered a blow today as the US Court of Appeals for the Federal Circuit affirmed a decision rejecting use of tribal sovereign immunity in the inter partes review (IPR).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Allergan and tribe hit back at Mylan claims in SCOTUS brief

20 March 2019 Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.

Americas

Seven states urge Fed Circuit to rehear tribal immunity case

10 September 2018 Seven states have urged the US Court of Appeals for the Federal Circuit to rehear a decision rejecting the use of tribal sovereign immunity in the inter partes review process.

Americas

Allergan-tribe ruling raises questions over immunity at PTAB: lawyers

24 July 2018 The US Court of Appeals for the Federal Circuit’s ruling that tribal sovereign immunity doesn’t apply in inter partes review proceedings has sparked questions over state protections at the Patent Trial and Appeal Board.